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Atrial septal defect (ASD) is a congenital heart defect often
ncountered in the adult population, because many patients are
ree from overt symptoms for the ﬁrst few decades and may
how  limited physical signs. Pulmonary arterial hypertension
PAH) complicating to left-to-right shunting at the atrial level
s  seen in 6–35% of untreated patients in later adulthood [1–3].
he  presence of PAH is associated with older age, female sex,
nd  defect size and causes progressive dyspnea, ascites, edema,
resyncope  or syncope, functional limitations, persistent right ven-
ricular dilation and signiﬁcant tricuspid regurgitation after closure
f  ASD, and increased mid-to-long-term morbidity and mortality
4–8].  Although the exact pathogenesis of PAH in patients with
SD  is not clearly deﬁned, it has been postulated that increased
ulmonary ﬂow leads to pulmonary endothelial damage with
esultant  leukocyte activation and release of mediators, ultimately
ausing  vasoconstriction and eventual vascular hypertrophy [9].
he prevalence of Heath–Edwards grade 4 to 6 by histopathology
f  lung biopsy specimens was observed in 6% of adult patients who
nderwent surgical ASD closure. Histological changes in the intima
nd media of the pulmonary vessels can result in luminal narrow-
ng  and subsequent development of PAH. PAH can occur in adults
ith  ASD as a result of chronic exposure of the pulmonary vessels
o  increased blood ﬂow through the shunt.
AH after ASD closure in adults
Patients with moderate or severe PAH may  beneﬁt from
ubstantial reductions in pulmonary artery pressures after ASD
losure,  although pulmonary artery pressures remain elevated
n  a sizable population. A reduction in pulmonary arterial sys-
olic  pressure >5 mmHg  was noted in 34%, 74%, 79%, and 100%
f  patients with no, mild, moderate, and severe baseline PAH,
espectively [7]. Balint et al. [2] showed that systolic pulmonary
rtery  pressure decreased from 58 to 44 mmHg  in ASD patients
ith  PAH who have undergone percutaneous closure after a mean
ollow-up  of 31 months. The proportion of patients with New York
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ttp://dx.doi.org/10.1016/j.jccase.2012.04.005eart Association functional class III or IV symptoms was reduced
y  80% after transcatheter ASD closure [7].
Right ventricular enlargement, persistent PAH, and clinical heart
ailure  development late after percutaneous ASD closure are seen
ore frequently in elderly patients. ASD closure for patients with
AH  may  induce further elevation of pulmonary arterial pressure
nd  reduction in cardiac output.
As for arrhythmias, a signiﬁcant relative risk reduction in the
ncidence  of atrial tachyarrhythmia was noted after ASD closure.
owever,  no reduction in the incidence of atrial tachyarrhythmia
as noted after ASD closure in patients with severe PAH.
valuation before ASD closure in patients with PAH
ASD  closure is associated with an increased post-procedural
ortality in elderly patients with PAH. Once severe PAH or Eisen-
enger  syndrome has developed, ASD closure is problematic due
o the increased risk of right ventricular failure and pulmonary
ypertensive crisis. For avoidance of such a serious situation, some
riteria were used to determine the operability of ASD patients
ith  PAH. Cyanosis from right-to-left shunting at the atrial level is
ndicative of severe PAH. A hemodynamic study during temporary
alloon  test occlusion of ASD can be a good indicator of the subse-
uent  evolution of PAH. If a drop in cardiac output or an increase in
ight ventricular ﬁlling pressure occurs with test balloon occlusion,
t  is indicative of a low likelihood of beneﬁt from ASD closure.
ulmonary vasodilators for patients with PAH before and
fter  ASD closure
A  recent large US-based registry suggested that PAH associated
ith  congenital heart disease is more likely to be responsive to
asodilatory  change than other forms of PAH [10]. For ASD patients
ith  severe PAH, successful surgical ASD closure followed by post-
perative reduction of pulmonary artery pressure using long-term
rostacyclin treatment has been reported. Afterward, many reports
ndicated  that ASD closure is possible in selected patients with
evere  PAH after advanced therapy with pulmonary vasodilators,
.e.  oral bosentan, intravenous epoprostenol, and oral sildenaﬁl
11–14].trial  septostomy for patients with PAH after ASD closure
In  the presence of severe PAH, ASD would function as a safety
alve  to unload the right ventricle preserving its function and
vier Ltd. All rights reserved.
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aintaining systemic output, despite the risk of hypoxia and
yanosis  [15]. In addition, the natural history of idiopathic PAH
ay  be better if a patent foramen ovale allows a reduction in right
eart  overextension by right-to-left shunting. For these reasons,
ercutaneous atrial septostomy is recommended for patients with
evere PAH and intractable right heart failure despite maximal
AH-speciﬁc agents and inotropes as palliative treatment or bridge
o transplantation [16,17]. Atrial septostomy creates a right-to-left
nteratrial  shunt, decreasing right heart ﬁlling pressures and
mproving  right heart function and left heart ﬁlling. While the
reated  shunt decreases systemic arterial oxygen saturation, it
s anticipated that the improved cardiac output will result in
verall  augmentation of systemic oxygen delivery. Improved
ardiac output is considered to be the principal hemodynamic
eneﬁt. Kapoor et al. [18] reported hemodynamic and clinical
mprovement following the atrial septostomy of severe PAH using
 unique technique. A major shortcoming of atrial septostomy
s  relatively high incidence of spontaneous closure or decrease
n  oriﬁce size that requires repeat septostomy. Consequently,
mplantation of a fenestrated septostomy device in PAH proved
uccessful  in long-term follow-up [19].
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